Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.
Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company's worth by up to 30%.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company's U.S. business has struggled with the rise of GLP-1 drugs and declining margins.
